Inhibrx Biosciences Reports Promising Q3 2025 Results
Inhibrx Biosciences reported promising Q3 2025 results, highlighting progress in clinical trials, especially for ozekibart (INBRX-109) in treating chondrosarcoma. Financially, the company saw a decrease in cash to $153.1 million and reduced R&D expenses to $28.5 million. Despite a net loss of $35.3 million, this was an improvement from the previous year. Inhibrx plans to submit a biologics license application for ozekibart in 2026, with positive interim data for colorectal cancer and Ewing sarcoma programs.
Inhibrx Biosciences, Inc. ( (INBX) ) has released its Q3 earnings. Here is a breakdown of the information Inhibrx Biosciences, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, utilizing advanced protein engineering platforms to address complex disease biology.
In its third-quarter 2025 earnings report, Inhibrx highlighted significant progress in its clinical trials, particularly with its therapeutic candidate ozekibart (INBRX-109), which showed promising results in treating chondrosarcoma. The company also provided updates on its colorectal cancer and Ewing sarcoma programs.
Financially, Inhibrx reported a decrease in cash and cash equivalents to $153.1 million from $186.6 million in the previous quarter. The company reduced its research and development expenses to $28.5 million, down from $38.9 million in the same period last year, primarily due to decreased process development and manufacturing activities. General and administrative expenses also fell to $5.3 million from $7.9 million, attributed to lower legal and personnel-related costs. Despite these reductions, the company posted a net loss of $35.3 million, an improvement from the $43.9 million loss in the third quarter of 2024.
Strategically, Inhibrx plans to submit a biologics license application for ozekibart to the U.S. Food and Drug Administration in the second quarter of 2026, following the positive outcomes of its trials. The interim data from its expansion cohorts in colorectal cancer and Ewing sarcoma also indicate high response rates, showcasing the potential of its therapeutic candidates.
Looking ahead, Inhibrx remains focused on advancing its clinical pipeline and optimizing its therapeutic candidates to address unmet medical needs, while managing its financial resources to support ongoing and future developments.
